Foshan Ionova Biotherapeutics Co. Ltd. has described proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin-protein ligase binding moiety covalently linked to an androgen receptor variant 7 (AR-v7) targeting moiety acting as AR-v7 degradation inducers reported to be useful for the treatment of prostate cancer.
Astrazeneca AB has synthesized transient receptor potential cation channel subfamily V member 4 (TRPV4) antagonists reported to be useful for the treatment of inflammatory disorders, respiratory diseases, metabolic diseases, dermatological disorders, neuromuscular disorders, genetic disorders, cancer and pain, among others.
Haisco Pharmaceutical Group Co. Ltd. has disclosed fibroblast growth factor receptor 2 (FGFR2) inhibitors reported to be useful for the treatment of cancer.
Rivo Bio Inc. has disclosed compounds acting as 5-HT2A receptor agonists reported to be useful for the treatment of depression, schizophrenia and anxiety disorders.
Hefei Institutes of Physical Science Chinese Academy of Sciences has synthesized phosphoglycerate kinase 1 (PGK1) inhibitors reported to be useful for the treatment of inflammatory bowel disease.
Shanghai Fosun Pharmaceutical Industry Development Co. Ltd. has identified drug-conjugates comprising a radionuclide-labeled molecular probe linked to ligand targeting fibroblast activation protein α (FAP) through a linker reported to be useful for the treatment and diagnosis of cancer.
Alicorn Pharmaceutical Co. Ltd. has synthesized protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer, genetic disorders, cardiovascular disorders, and inflammation, autoimmune, hematologic, liver and metabolic diseases, among others.
Shanghai Ruotuo Biotechnology Co. Ltd. has identified antibody-drug conjugates consisting of antibodies targeting HER2 (erbB2) covalently linked to camptothecin derivatives through a linker reported to be useful for the treatment of cancer.
RSS